Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q4 FY24 results · Jan–Mar 2024
Procter & Gamble Health reported revenue from operations of ₹252.48 crore (down 21.3% from Q4 FY23) and net profit of ₹46.56 crore (down 21.3% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a standalone basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 252.48 | 320.92 | −21.3% | 309.97 | −18.5% |
| Other income | 2.27 | 4.97 | −54.3% | 5.18 | −56.2% |
| Total income | 254.75 | 325.89 | −21.8% | 315.15 | −19.2% |
| Profit before tax | 62.72 | 78.53 | −20.1% | 99.72 | −37.1% |
| Net profit for the period | 46.56 | 59.19 | −21.3% | 72.07 | −35.4% |
| EPS, basic (₹) | 28.00 | 35.70 | −21.6% | 43.40 | −35.5% |
| Net margin (%) | 18.4 | 18.4 | 23.3 |
Standalone
- Filed with BSE
- 03 May 2024, 16:20 IST
- Board meeting
- 02 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE